SOM Biotech will attend the “BIO-Europe 2020” convention on October 26th – 29th, which will take place digitally due to the pandemic situation.
Raúl Insa, CEO of SOM Biotech: “BIO-Europe 2020 is one of the most relevant partnering events for the life science sector. We look forward to meeting with potential partners and qualified investors to explore partnerships and to present our strategic guidelines, which shall strengthen SOM Biotech´s future growth. SOM Biotech is uniquely positioned to generate value with a robust pipeline with two successful Phase 2 drug candidates and four products in pre-clinical positioned to reach Phase 2 in 2021 for the treatment of orphan, CNS, and acute diseases in other therapeutic areas.
. Additionally, the high efficacy and versatility of our pioneering AI-based drug discovery platform enables us to develop strategic partnerships with pharmaceutical companies to identify novel drug targets as well as to rescue and reposition existing drugs. With our partners, we aim at fostering innovation, generating additional value, and increasing the lifecycle of drugs.”
You can find more information about BIO-Europe 2020 Digital Convention here.